This site is intended for healthcare professionals

MHRA (UK) approves Tukysa for the treatment of advanced HER2-positive breast cancer.- Seagen

Read time: 1 mins
Last updated:28th Jun 2021
Published:24th Feb 2021
Condition: Breast Cancer HER2+
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest